Diagnostic application of serum proteomic patterns in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

International Journal of Biological Markers

Volumn 22, Issue 4, 2007, Pages 281-286

  Lim, J Y ^a   Cho, Jae Yong ^a   Paik, Y H ^a   Chang, Y S ^a   Kim, H G ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Gastric cancer; Protein pattern profiling; SELDI TOF MS

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 39149131748     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.1632     Document Type: Article

References (32)

1. Central Cancer Registry. Annual Report. Korea: Central Cancer Registry 2001.
2. Alberts SR, Cervantes A, Velde CJH. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003; 14 (Suppl 2): ii31-ii36.
3. Spataro V, Genoni M, Maurer C, Muller W. Stomach cancer: 10 years' experience with surgical treatment and possibilities for improving the prognosis. Helv Chir Acta 1993; 59: 589-95.
4. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987; 11: 418-25.
5. Bunt AM, Hermans J, Smit VT, van de Velde CJ, Fleuren GJ, Bruijn JA. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995; 13: 19-25.
6. Froehlich F, Gonvers JJ, Vader JP, Dubois RW, Burnaud B. Appropriateness of gastrointestinal endoscopy: Risk of complications. Endoscopy 1999; 31: 684-6.
7. Petricoin EF, Liotta, LA. Proteomic approaches in cancer risk and response assessment. Trends Mol Med 2004; 10: 59-64.
8. Tyers M, Mann M. From genomics to proteomics. Nature 2003; 422: 193-7.
9. Anderson NL, Matheson AD, Steiner S. Proteomics: Applications in basic and applied biology. Curr Opin Biotechnol 2000; 11: 408-12.
10. Seibert V, Ebert MP, Buschmann T. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic 2005; 4: 16-26.
11. Pectasides D, Mylonakis A, Kostopoulou M, et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 1997; 20: 348-53.
12. Marrelli D, Roviello F, De Stefano A, et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999; 57: 55-62.
13. Carpelan-Holmstorm M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002; 22: 2311-6.
14. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ. Proteomic patterns: their potential for disease diagnosis. Mol Cell Endocrinol 2005; 230: 95-106.
15. Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD. SELDI-TOF MS for diagnostic proteomics. Anal Chem 2003; 75: 148-55.
16. Wiesner A. Detection of tumor markers with ProteinChip technology. Curr Pharm Biotechnol 2004; 5: 45-67.
17. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
18. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005; 97: 307-9.
19. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling - a young technology begins to mature. Nat Biotechnol 2005; 23: 291-2.
20. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-90.
21. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004; 96: 353-6.
22. Diamandis EP, Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 2005; 11: 963-5.
23. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005; 97: 315-9.
24. Yang SY, Xiao XY, Zhang WG, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005; 5: 83.
25. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-304.
26. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-14.
27. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using sufface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 860-8.
28. Qian HG, Shen J, Ma H, et al. Preliminary study on preoteomics of gastric carcinoma and its clinical significance. World J Gastroenterol 2005; 11: 6249-58.
29. Su Y, Shen J, Quian H, et al. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci 2007; 98: 37-43.
30. Ebert MP, Meuer J, Wiemer JC, et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res 2004; 3: 1261-6.
31. Liang Y, Fang M, Li J, et al. Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol 2006; 81: 176-80.
32. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol Cell Proteomics 2004; 3: 367-78.